Enhancing the functional maturity of induced pluripotent stem cell-derived human hepatocytes by controlled presentation of cell-cell interactions in vitro

Hepatology

Volumn 61, Issue 4, 2015, Pages 1370-1381

  Berger, Dustin R ^a   Ware, Brenton R ^a   Davidson, Matthew D ^a   Allsup, Samuel R ^a   Khetani, Salman R ^a  

^a Engineering Research Center and Hydraulics Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; ARGINASE 1; CYTOCHROME P450; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; GROWTH FACTOR; HEPATOCYTE NUCLEAR FACTOR 6; IMMUNOGLOBULIN G ANTIBODY; LOW DENSITY LIPOPROTEIN; UREA;

ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL INTERACTION; CELL MATURATION; CONJUGATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG INTERACTION; DRUG METABOLISM; DRUG SCREENING; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE REGULATORY NETWORK; HUMAN; HUMAN CELL; IN VITRO STUDY; INDUCED PLURIPOTENT STEM CELL DERIVED HUMAN HEPATOCYTE LIKE CELL; INTRAHEPATIC BILE DUCT; LIVER CELL; LIVER FUNCTION; LIVER TOXICITY; LONGEVITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; STABLE EXPRESSION; UREA CYCLE; CELL COMMUNICATION; CELL CULTURE; CULTURE TECHNIQUE; DEVICES; PHYSIOLOGY; TIME;

CELL COMMUNICATION; CELL CULTURE TECHNIQUES; CELLS, CULTURED; HEPATOCYTES; HUMANS; INDUCED PLURIPOTENT STEM CELLS; TIME FACTORS;

EID: 84925307610     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27621     Document Type: Article

References (40)

1. Godoy P, Hewitt NJ, Albrecht U, Andersen ME, Ansari N, Bhattacharya S, et al. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol 2013;87:1315-1530.
2. LeCluyse EL, Witek RP, Andersen ME, Powers MJ. Organotypic liver culture models: meeting current challenges in toxicity testing. Crit Rev Toxicol 2012;42:501-548.
3. Wilkening S, Stahl F, Bader A. Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties. Drug Metab Dispos 2003;31:1035-1042.
4. Gerets HHJ, Tilmant K, Gerin B, Chanteux H, Depelchin BO, Dhalluin S, et al. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol 2012;28:69-87.
5. Guillouzo A. Liver cell models in in vitro toxicology. Environ Health Perspect 1998;106 Suppl 2:511-532.
6. Khetani SR, Bhatia SN. Microscale culture of human liver cells for drug development. Nat Biotechnol 2008;26:120-126.
7. Gerbal-Chaloin S, Funakoshi N, Caillaud A, Gondeau C, Champon B, Si-Tayeb K. Human induced pluripotent stem cells in hepatology: beyond the proof of concept. Am J Pathol 2014;184:332-347.
8. Scott CW, Peters MF, Dragan YP. Human induced pluripotent stem cells and their use in drug discovery for toxicity testing. Toxicol Lett 2013;219:49-58.
9. Engle SJ, Puppala D. Integrating human pluripotent stem cells into drug development. Cell Stem Cell 2013;12:669-677.
10. Schwartz RE, Fleming HE, Khetani SR, Bhatia SN. Pluripotent stem cell-derived hepatocyte-like cells. Biotechnol Adv 2014;32:504-513.
11. Si-Tayeb K, Noto FK, Nagaoka M, Li J, Battle MA, Duris C, et al. Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology 2010;51:297-305.
12. Ma X, Duan Y, Tschudy-Seney B, Roll G, Behbahan IS, Ahuja TP, et al. Highly efficient differentiation of functional hepatocytes from human induced pluripotent stem cells. Stem Cells Transl Med 2013;2:409-419.
13. Zhu S, Rezvani M, Harbell J, Mattis AN, Wolfe AR, Benet LZ, et al. Mouse liver repopulation with hepatocytes generated from human fibroblasts. Nature 2014;508:93-97.
14. Touboul T, Hannan NRF, Corbineau S, Martinez A, Martinet C, Branchereau S, et al. Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development. Hepatology 2010;51:1754-1765.
15. Du Y, Wang J, Jia J, Song N, Xiang C, Xu J, et al. Human hepatocytes with drug metabolic function induced from fibroblasts by lineage reprogramming. Cell Stem Cell 2014;14:394-403.
16. Song Z, Cai J, Liu Y, Zhao D, Yong J, Duo S, et al. Efficient generation of hepatocyte-like cells from human induced pluripotent stem cells. Cell Res 2009;19:1233-1242.
17. Chen YF, Tseng CY, Wang HW, Kuo HC, Yang VW, Lee OK. Rapid generation of mature hepatocyte-like cells from human induced pluripotent stem cells by an efficient three-step protocol. Hepatology 2012;55:1193-1203.
18. Huang P, Zhang L, Gao Y, He Z, Yao D, Wu Z, et al. Direct reprogramming of human fibroblasts to functional and expandable hepatocytes. Cell Stem Cell 2014;14:370-384.
19. Bhatia SN, Balis UJ, Yarmush ML, Toner M. Effect of cell-cell interactions in preservation of cellular phenotype: cocultivation of hepatocytes and nonparenchymal cells. FASEB J 1999;13:1883-1900.
20. Wang WW, Khetani SR, Krzyzewski S, Duignan DB, Obach RS. Assessment of a micropatterned hepatocyte coculture system to generate major human excretory and circulating drug metabolites. Drug Metab Dispos [Internet] 2010;38:1900-1905.
21. Khetani SR, Kanchagar C, Ukairo O, Krzyzewski S, Moore A, Shi J, et al. Use of micropatterned cocultures to detect compounds that cause drug-induced liver injury in humans. Toxicol Sci 2013;132:107-117.
22. Stevens KR, Ungrin MD, Schwartz RE, Ng S, Carvalho B, Christine KS, et al. InVERT molding for scalable control of tissue microarchitecture. Nat Commun 2013;4:1847.
23. Takebe T, Sekine K, Enomura M, Koike H, Kimura M, Ogaeri T, et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature 2013;499:481-484.
24. Nagamoto Y, Tashiro K, Takayama K, Ohashi K, Kawabata K, Sakurai F, et al. The promotion of hepatic maturation of human pluripotent stem cells in 3D co-culture using type I collagen and Swiss 3T3 cell sheets. Biomaterials 2012;33:4526-4534.
25. Javed MS, Yaqoob N, Iwamuro M, Kobayashi N, Fujiwara T. Generation of hepatocyte-like cells from human induced pluripotent stem (iPS) cells by co-culturing embryoid body cells with liver non-parenchymal cell line TWNT-1. J Coll Physicians Surg Pak 2014;24:91-96.
26. Baxter MA, Rowe C, Alder J, Harrison S, Hanley KP, Park BK, et al. Generating hepatic cell lineages from pluripotent stem cells for drug toxicity screening. Stem Cell Res 2010;5:4-22.
27. Novik E, Maguire TJ, Chao P, Cheng KC, Yarmush ML. A microfluidic hepatic coculture platform for cell-based drug metabolism studies. Biochem Pharmacol 2010;79:1036-1044.
28. Sasaki T, Takahashi S, Numata Y, Narita M, Tanaka Y, Kumagai T, et al. Hepatocyte nuclear factor 6 activates the transcription of CYP3A4 in hepatocyte-like cells differentiated from human induced pluripotent stem cells. Drug Metab Pharmacokinet 2013;28:250-259.
29. Prueksaritanont T, Chu X, Gibson C, Cui D, Yee KL, Ballard J, et al. Drug-drug interaction studies: regulatory guidance and an industry perspective. AAPS J 2013;15:629-645.
30. Szkolnicka D, Farnworth SL, Lucendo-Villarin B, Storck C, Zhou W, Iredale JP, et al. Accurate prediction of drug-induced liver injury using stem cell-derived populations. Stem Cells Transl Med 2014;3:141-148.
31. Cahan P, Li H, Morris SA, Lummertz da Rocha E, Daley GQ, Collins JJ. CellNet: network biology applied to stem cell engineering. Cell 2014;158:903-915.
32. March S, Ng S, Velmurugan S, Galstian A, Shan J, Logan DJ, et al. A microscale human liver platform that supports the hepatic stages of Plasmodium falciparum and vivax. Cell Host Microbe 2013;14:104-115.
33. Khetani SR, Szulgit G, Del Rio JA, Barlow C, Bhatia SN. Exploring interactions between rat hepatocytes and nonparenchymal cells using gene expression profiling. Hepatology 2004;40:545-554.
34. Ukairo O, Kanchagar C, Moore A, Shi J, Gaffney J, Aoyama S, et al. Long-term stability of primary rat hepatocytes in micropatterned cocultures. J Biochem Mol Toxicol 2013;27:204-212.
35. Khetani SR, Chen AA, Ranscht B, Bhatia SN. T-cadherin modulates hepatocyte functions in vitro. FASEB J 2008;22:3768-3775.
36. Gieseck RL, Hannan NRF, Bort R, Hanley NA, Drake RAL, Cameron GWW, et al. Maturation of induced pluripotent stem cell derived hepatocytes by 3D-culture. PLoS One 2014;9:e86372.
37. Takayama K, Kawabata K, Nagamoto Y, Kishimoto K, Tashiro K, Sakurai F, et al. 3D spheroid culture of hESC/hiPSC-derived hepatocyte-like cells for drug toxicity testing. Biomaterials 2013;34:1781-1789.
38. Shan J, Schwartz RE, Ross NT, Logan DJ, Thomas D, Duncan SA, et al. Identification of small molecules for human hepatocyte expansion and iPS differentiation. Nat Chem Biol 2013;9:514-520.
39. Liu H, Ye Z, Kim Y, Sharkis S, Jang YY. Generation of endoderm-derived human induced pluripotent stem cells from primary hepatocytes. Hepatology 2010;51:1810-1819.
40. Xu JJ, Henstock PV, Dunn MC, Smith AR, Chabot JR, de Graaf D. Cellular imaging predictions of clinical drug-induced liver injury. Toxicol Sci 2008;105:97-105.